Pyxis Oncology (PYXS) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 45.9% versus a loss of 31.6%. Over five years, PYXS leads with a -83.1% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $242.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | ZNTL |
|---|---|---|
| Share price | $2.03 | $2.64 |
| Market cap | $242.50M | $259.04M |
| 1-day change | +2.01% | +5.18% |
| YTD return | +73.04% | +95.56% |
| 1-year return | -31.62% | +45.86% |
| 5-year return | -83.09% | -96.48% |
| EPS (TTM) | $-1.40 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $6.95 |
| 52-week low | $1.03 | $1.21 |
| Distance from 52-week high | -63.42% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +327.09% | +177.65% |
| Average volume | 1.26M | 1.21M |
| Shares outstanding | 119.46M | 98.12M |
| Employees | 56 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed PYXS by 77.5 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
PYXS vs ZNTL FAQ
Which is bigger, Pyxis Oncology or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $242.50M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.